David J. Csordas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David J. Csordas has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Shayn Peirce-Cottler
University of Virginia
4 shared publications Clare C. Flanagan
2 shared publications- Claudia Daboin
Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, 22903, USA
2 shared publications - Donald Richieri Griffin
Department of Biomedical Engineering, University of Virginia, Charlottesville, VA
2 shared publications John Catechis
2 shared publications- John Shinn Kim
University of Virginia
2 shared publications
Latest Publications
Markers of microvascular instability predict severity and survival in idiopathic pulmonary fibrosis
Introduction: Most research on idiopathic pulmonary fibrosis (IPF) has focused on the interplay among fibroblasts, the immune system and epithelial cells. There is growing evidence that microvascular dysfunction also plays a role in disease progression, but large human translational studies are lacking. In this research, we aim to identify a proteomic signature of microvascular instability and assess the impact of current therapeutics on the microvasculature. Methods: Olink proteomic data from patients with IPF were obtained from the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR) (n=914) and an independent validation cohort (n=366). Among the PFF-PR, 640 patients also have whole-blood RNA sequencing data available. A subset of 79 microvascular-associated proteins was curated, and their associations with disease severity and transplant-free survival were examined. An adaptive least absolute shrinkage and selection operator was used to generate a novel microvascular risk score. Results: Higher plasma levels of five microvascular-associated proteins (SDC1, MMP10, THBS2, HGF and SERPINA5) were associated with lung function and survival in both cohorts. Whole-blood RNA sequencing of patients with microvascular risk revealed enrichment of immune-mediated processes. Patients with higher microvascular risk who were subsequently put on nintedanib in the following year had significantly better 3-year transplant-free survival compared with patients who did not receive antifibrotic intervention (HR 0.56, 95% CI 0.35 to 0.89, p=0.0142). Discussion: Integrative multi-omics analyses suggest that perturbations to microvascular remodelling contribute to disease severity and progression in IPF. This analysis offers a framework for a precision medicine approach for IPF.
Markers of microvascular instability predict severity and survival in idiopathic pulmonary fibrosis
Introduction: Most research on idiopathic pulmonary fibrosis (IPF) has focused on the interplay among fibroblasts, the immune system and epithelial cells. There is growing evidence that microvascular dysfunction also plays a role in disease progression, but large human translational studies are lacking. In this research, we aim to identify a proteomic signature of microvascular instability and assess the impact of current therapeutics on the microvasculature. Methods: Olink proteomic data from patients with IPF were obtained from the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR) (n=914) and an independent validation cohort (n=366). Among the PFF-PR, 640 patients also have whole-blood RNA sequencing data available. A subset of 79 microvascular-associated proteins was curated, and their associations with disease severity and transplant-free survival were examined. An adaptive least absolute shrinkage and selection operator was used to generate a novel microvascular risk score. Results: Higher plasma levels of five microvascular-associated proteins (SDC1, MMP10, THBS2, HGF and SERPINA5) were associated with lung function and survival in both cohorts. Whole-blood RNA sequencing of patients with microvascular risk revealed enrichment of immune-mediated processes. Patients with higher microvascular risk who were subsequently put on nintedanib in the following year had significantly better 3-year transplant-free survival compared with patients who did not receive antifibrotic intervention (HR 0.56, 95% CI 0.35 to 0.89, p=0.0142). Discussion: Integrative multi-omics analyses suggest that perturbations to microvascular remodelling contribute to disease severity and progression in IPF. This analysis offers a framework for a precision medicine approach for IPF.
- Open Access
A novel in vitro assay for quantifying endothelial cell and pericyte interactions
Objective: Structural adaptations of capillary networks, through angiogenesis, arterialization, and regression, are implicated in many diseases, and gaining a better understanding of the cell-cell interactions that underpin these adaptations may lead to novel therapeutic discoveries for disease management. Endothelial cells and pericytes are the two cell types that comprise capillary networks. Experimental model systems have been developed to study the dynamic interactions between endothelial cells and pericytes, providing valuable insights into capillary development, cell-to-cell communication, and responses to growth factors and therapeutic agents. Methods: In this study, we present a novel and simple co-culture system that uses commercially available primary human endothelial cells and pericytes, does not require microfluidic perfusion, and allows simultaneous observation of cell morphologies and interactions over time in 60 samples, enabling high-throughput analysis of multiple culture conditions with replicates. Results: Image analysis pipelines were created to quantify microvascular adaptations, including one to measure colocalization between endothelial cells and pericytes, capturing dynamic coupling and uncoupling associated with capillary stability, angiogenesis, and regression. We validated the ability of our co-culture system to reproducibly represent the effects of fibrotic and angiogenic activation signals, including an FDA-approved drug, on endothelial cells, pericytes, and their coupling. Conclusion: This novel, high-throughput microvascular screening assay enables quantification of microvascular dynamics in response to disease-relevant stimuli and therapeutics in a repeatable, real-time manner.
Open AccessA novel in vitro assay for quantifying endothelial cell and pericyte interactions
Objective: Structural adaptations of capillary networks, through angiogenesis, arterialization, and regression, are implicated in many diseases, and gaining a better understanding of the cell-cell interactions that underpin these adaptations may lead to novel therapeutic discoveries for disease management. Endothelial cells and pericytes are the two cell types that comprise capillary networks. Experimental model systems have been developed to study the dynamic interactions between endothelial cells and pericytes, providing valuable insights into capillary development, cell-to-cell communication, and responses to growth factors and therapeutic agents. Methods: In this study, we present a novel and simple co-culture system that uses commercially available primary human endothelial cells and pericytes, does not require microfluidic perfusion, and allows simultaneous observation of cell morphologies and interactions over time in 60 samples, enabling high-throughput analysis of multiple culture conditions with replicates. Results: Image analysis pipelines were created to quantify microvascular adaptations, including one to measure colocalization between endothelial cells and pericytes, capturing dynamic coupling and uncoupling associated with capillary stability, angiogenesis, and regression. We validated the ability of our co-culture system to reproducibly represent the effects of fibrotic and angiogenic activation signals, including an FDA-approved drug, on endothelial cells, pericytes, and their coupling. Conclusion: This novel, high-throughput microvascular screening assay enables quantification of microvascular dynamics in response to disease-relevant stimuli and therapeutics in a repeatable, real-time manner.
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Cellularized Hydrogel-Interfaced Cantilever (CHIC) Biosensors for Monitoring 3D Cell Culture Mechanical Properties
Sensors that employ and interface with cell-laden hydrogels can be used to identify novel cell signal transduction mechanisms, facilitate the detection of novel analytes, and test the effects of environmental perturbations on cell behavior, such as microgravity and drug exposure. Here, we report a novel cellularized hydrogel-interfaced cantilever (CHIC) biosensor for continuously monitoring the mechanical properties of 3D cell co-cultures in hydrogels. CHIC biosensors interfaced with 3D microporous annealed particle hydrogels laden with co-cultured fibroblasts and endothelial cells enabled monitoring of changes in the culture stiffness and the response to TGF-β1 stimulation over time via a mechanobiological transduction mechanism. 3D cell culture responses to the growth factor TGF-β1 (10 ng/mL) were associated with a change in the biosensor phase angle at resonance (ϕ). Long-term studies using CHIC biosensor arrays in a 3D co-culture assay over three weeks showed that TGF-β1 stimulation-induced changes in biosensor ϕ were consistent with changes in compressive modulus measured by an independent destructive testing method. The biosensor response and results of independent destructive mechanical characterization were corroborated by gene and protein expression analysis. The decrease in ϕ following TGF-β1 stimulation was correlated with upregulation of ACTA2, IL6, COL4A1, CXCL10, downregulation of MMP1, IL1R1, and CXCL8 in fibroblasts and endothelial cells. Meanwhile, expressions of PDGF-BB and IFN-γ remained elevated compared to the unstimulated control throughout the time course. This work establishes a new biosensor that enables mechanical property sensing of hydrogel-based 3D cell co-culture models.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCellularized Hydrogel-Interfaced Cantilever (CHIC) Biosensors for Monitoring 3D Cell Culture Mechanical Properties
Sensors that employ and interface with cell-laden hydrogels can be used to identify novel cell signal transduction mechanisms, facilitate the detection of novel analytes, and test the effects of environmental perturbations on cell behavior, such as microgravity and drug exposure. Here, we report a novel cellularized hydrogel-interfaced cantilever (CHIC) biosensor for continuously monitoring the mechanical properties of 3D cell co-cultures in hydrogels. CHIC biosensors interfaced with 3D microporous annealed particle hydrogels laden with co-cultured fibroblasts and endothelial cells enabled monitoring of changes in the culture stiffness and the response to TGF-β1 stimulation over time via a mechanobiological transduction mechanism. 3D cell culture responses to the growth factor TGF-β1 (10 ng/mL) were associated with a change in the biosensor phase angle at resonance (ϕ). Long-term studies using CHIC biosensor arrays in a 3D co-culture assay over three weeks showed that TGF-β1 stimulation-induced changes in biosensor ϕ were consistent with changes in compressive modulus measured by an independent destructive testing method. The biosensor response and results of independent destructive mechanical characterization were corroborated by gene and protein expression analysis. The decrease in ϕ following TGF-β1 stimulation was correlated with upregulation of ACTA2, IL6, COL4A1, CXCL10, downregulation of MMP1, IL1R1, and CXCL8 in fibroblasts and endothelial cells. Meanwhile, expressions of PDGF-BB and IFN-γ remained elevated compared to the unstimulated control throughout the time course. This work establishes a new biosensor that enables mechanical property sensing of hydrogel-based 3D cell co-culture models.
- 10 June 2026
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 311, 118912
Cellularized hydrogel-interfaced cantilever (CHIC) biosensors for monitoring 3D cell culture mechanical properties
- 10 June 2026
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 311, 118912
Cellularized hydrogel-interfaced cantilever (CHIC) biosensors for monitoring 3D cell culture mechanical properties
- Open Access
- 7 December 2024
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 4 (1) , pgae551
Multiscale computational model predicts how environmental changes and treatments affect microvascular remodeling in fibrotic disease
Investigating the molecular, cellular, and tissue-level changes caused by disease, and the effects of pharmacological treatments across these biological scales, necessitates the use of multiscale computational modeling in combination with experimentation. Many diseases dynamically alter the tissue microenvironment in ways that trigger microvascular network remodeling, which leads to the expansion or regression of microvessel networks. When microvessels undergo remodeling in idiopathic pulmonary fibrosis (IPF), functional gas exchange is impaired and lung function declines. We integrated a multiscale computational model with independent experiments to investigate how combinations of biomechanical and biochemical cues in IPF alter cell fate decisions leading to microvascular remodeling. Our computational model predicted that extracellular matrix (ECM) stiffening reduced microvessel area, which was accompanied by physical uncoupling of endothelial cell (EC) and pericytes, the cells that comprise microvessels. Nintedanib, an Food and Drug Administration-approved drug for treating IPF, was predicted to further potentiate microvessel regression by decreasing the percentage of quiescent pericytes while increasing the percentage of pericytes undergoing pericyte-myofibroblast transition in high ECM stiffnesses. Importantly, the model suggested that YAP/TAZ inhibition may overcome the deleterious effects of nintedanib by promoting EC-pericyte coupling and maintaining microvessel homeostasis. Overall, our combination of computational and experimental modeling can predict and explain how cell decisions affect tissue changes during disease and in response to treatments.
- 7 December 2024
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 4 (1) , pgae551
Open AccessMultiscale computational model predicts how environmental changes and treatments affect microvascular remodeling in fibrotic disease
Investigating the molecular, cellular, and tissue-level changes caused by disease, and the effects of pharmacological treatments across these biological scales, necessitates the use of multiscale computational modeling in combination with experimentation. Many diseases dynamically alter the tissue microenvironment in ways that trigger microvascular network remodeling, which leads to the expansion or regression of microvessel networks. When microvessels undergo remodeling in idiopathic pulmonary fibrosis (IPF), functional gas exchange is impaired and lung function declines. We integrated a multiscale computational model with independent experiments to investigate how combinations of biomechanical and biochemical cues in IPF alter cell fate decisions leading to microvascular remodeling. Our computational model predicted that extracellular matrix (ECM) stiffening reduced microvessel area, which was accompanied by physical uncoupling of endothelial cell (EC) and pericytes, the cells that comprise microvessels. Nintedanib, an Food and Drug Administration-approved drug for treating IPF, was predicted to further potentiate microvessel regression by decreasing the percentage of quiescent pericytes while increasing the percentage of pericytes undergoing pericyte-myofibroblast transition in high ECM stiffnesses. Importantly, the model suggested that YAP/TAZ inhibition may overcome the deleterious effects of nintedanib by promoting EC-pericyte coupling and maintaining microvessel homeostasis. Overall, our combination of computational and experimental modeling can predict and explain how cell decisions affect tissue changes during disease and in response to treatments.
- 1 November 2021
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 321 (5) , G500-G512
The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease
Mouse and human data implicate the NOD1 and NOD2 sensors of the intestinal microbiome and the associated signal transduction via the receptor interacting protein kinase 2 (RIPK2) as a potential key signaling node for the development of inflammatory bowel disease (IBD) and an attractive target for pharmacological intervention. The TRUC mouse model of IBD was strongly indicated for evaluating RIPK2 antagonism for its effect on intestinal inflammation based on previous knockout studies with NOD1, NOD2, and RIPK2. We identified and profiled the BI 706039 molecule as a potent and specific functional inhibitor of both human and mouse RIPK2 and with favorable pharmacokinetic properties. We dosed BI 706039 in the spontaneous TRUC mouse model from age 28 to 56 days. Oral, daily administration of BI 706039 caused dose-responsive and significant improvement in colonic histopathological inflammation, colon weight, and terminal levels of protein-normalized fecal lipocalin (all P values <0.001). These observations correlated with dose responsively increasing systemic levels of the BI 706039 compound, splenic molecular target engagement of RIPK2, and modulation of inflammatory genes in the colon. This demonstrates that a relatively low oral dose of a potent and selective RIPK2 inhibitor can modulate signaling in the intestinal immune system and significantly improve disease associated intestinal inflammation. NEW & NOTEWORTHY The RIPK2 kinase at the apex of microbiome immunosensing is an attractive target for pharmacological intervention. A low oral dose of a RIPK2 inhibitor leads to significantly improved intestinal inflammation in the murine TRUC model of colitis. A selective and potent inhibitor of the RIPK2 kinase may represent a new class of therapeutics that target microbiome-driven signaling for the treatment of IBD.
- 1 November 2021
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 321 (5) , G500-G512
The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease
Mouse and human data implicate the NOD1 and NOD2 sensors of the intestinal microbiome and the associated signal transduction via the receptor interacting protein kinase 2 (RIPK2) as a potential key signaling node for the development of inflammatory bowel disease (IBD) and an attractive target for pharmacological intervention. The TRUC mouse model of IBD was strongly indicated for evaluating RIPK2 antagonism for its effect on intestinal inflammation based on previous knockout studies with NOD1, NOD2, and RIPK2. We identified and profiled the BI 706039 molecule as a potent and specific functional inhibitor of both human and mouse RIPK2 and with favorable pharmacokinetic properties. We dosed BI 706039 in the spontaneous TRUC mouse model from age 28 to 56 days. Oral, daily administration of BI 706039 caused dose-responsive and significant improvement in colonic histopathological inflammation, colon weight, and terminal levels of protein-normalized fecal lipocalin (all P values <0.001). These observations correlated with dose responsively increasing systemic levels of the BI 706039 compound, splenic molecular target engagement of RIPK2, and modulation of inflammatory genes in the colon. This demonstrates that a relatively low oral dose of a potent and selective RIPK2 inhibitor can modulate signaling in the intestinal immune system and significantly improve disease associated intestinal inflammation. NEW & NOTEWORTHY The RIPK2 kinase at the apex of microbiome immunosensing is an attractive target for pharmacological intervention. A low oral dose of a RIPK2 inhibitor leads to significantly improved intestinal inflammation in the murine TRUC model of colitis. A selective and potent inhibitor of the RIPK2 kinase may represent a new class of therapeutics that target microbiome-driven signaling for the treatment of IBD.